177 related articles for article (PubMed ID: 17656468)
1. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.
Kotrbová V; Mrázová B; Moserová M; Martínek V; Hodek P; Hudeček J; Frei E; Stiborová M
Biochem Pharmacol; 2011 Sep; 82(6):669-80. PubMed ID: 21683692
[TBL] [Abstract][Full Text] [Related]
3. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
5. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
7. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
8. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
[TBL] [Abstract][Full Text] [Related]
9. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
[TBL] [Abstract][Full Text] [Related]
10. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
12. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
[TBL] [Abstract][Full Text] [Related]
13. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.
Stiborova M; Moserova M; Mrazova B; Kotrbova V; Frei E
Neuro Endocrinol Lett; 2010; 31 Suppl 2():26-35. PubMed ID: 21187821
[TBL] [Abstract][Full Text] [Related]
14. Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2.
Aimová D; Poljaková J; Kotrbová V; Moserová M; Frei E; Arlt VM; Stiborová M
Interdiscip Toxicol; 2008 Sep; 1(2):160-8. PubMed ID: 21218107
[TBL] [Abstract][Full Text] [Related]
15. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
[TBL] [Abstract][Full Text] [Related]
16. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
Stiborová M; Bieler CA; Wiessler M; Frei E
Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
[TBL] [Abstract][Full Text] [Related]
17. 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2.
Arlt VM; Hewer A; Sorg BL; Schmeiser HH; Phillips DH; Stiborova M
Chem Res Toxicol; 2004 Aug; 17(8):1092-101. PubMed ID: 15310241
[TBL] [Abstract][Full Text] [Related]
18. Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450.
Aimová D; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):437-40. PubMed ID: 16601806
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
Stiborová M; Indra R; Moserová M; Cerná V; Rupertová M; Martínek V; Eckschlager T; Kizek R; Frei E
Chem Res Toxicol; 2012 May; 25(5):1075-85. PubMed ID: 22390216
[TBL] [Abstract][Full Text] [Related]
20. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
